Highlights

  • Covaxin gets emergency use nod for 6-12 age group
  • Covaxin makers asked to submit safety data every
    15 days for 2 months.
  • After 2 months, data to be submitted monthly for up to 5 months

Latest news

RBI focuses on expanding UPI for cross-border payments

RBI focuses on expanding UPI for cross-border payments

Fardeen Khan's cinematic return: eyeing Bollywood & South

Fardeen Khan's cinematic return: eyeing Bollywood & South

Maharashtra CM advocates lawful approach to Aurangzeb Tomb Issue

Maharashtra CM advocates lawful approach to Aurangzeb Tomb Issue

Controversy & Triumph: India's glory in Champions Trophy 2025

Controversy & Triumph: India's glory in Champions Trophy 2025

India imposes anti-dumping duty on Trichloroisocyanuric Acid imports

India imposes anti-dumping duty on Trichloroisocyanuric Acid imports

Rohit Sharma dispels ODI retirement rumors post champions trophy win

Rohit Sharma dispels ODI retirement rumors post champions trophy win

Modi's Mauritius Visit: New chapter in India-Mauritius relations

Modi's Mauritius Visit: New chapter in India-Mauritius relations

Shiv Sena's Rajpurohit detained for extortion allegations

Shiv Sena's Rajpurohit detained for extortion allegations

Covid-19: Covaxin gets emergency use nod for 6-12 age group

India began vaccination of those aged less than 18 at the beginning of this year.

Covid-19: Covaxin gets emergency use nod for 6-12 age group

India's drug regulator has granted emergency use authorisation for Biological E's COVID-19 vaccine Corbevax for those aged five to 12 years and Bharat Biotech's Covaxin for children in the age group of six to 12 years, official sources said on Tuesday.

The approval by the Drugs Controller General of India (DCGI) comes following recommendations by the Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organisation(CDSCO).

The SEC had last week reviewed the application of both the companies seeking emergency use authorisation for Corbevax and Covaxin for use in children of five to 12 years and six to 12 years age group, respectively.

Biological E's Corbevax is being used to inoculate children against COVID-19 in the age group of 12 to 14 years. Covaxin has been granted Emergency Use Listing (EUL) by the DCGI for the age group of 12 to 18 years on December 24, 2021.

India began inoculating children aged 12-14 on March 16. The countrywide vaccination drive was rolled out on January 16 last year with healthcare workers getting inoculated in the first phase. Vaccination of frontline workers started from February 2 last year.

The next phase of COVID-19 vaccination commenced on March 1 last year for people over 60 years of age and those aged 45 and above with specified co-morbid conditions.

India launched vaccination for all people aged more than 45 years from April 1 last year. The government then decided to expand its vaccination drive by allowing everyone above 18 years of age to be inoculated against the viral disease from May 1 last year.

The next phase of vaccination commenced on January 3 for adolescents in the age group of 15-18 years.

India began administering precaution doses of vaccines to healthcare and frontline workers and those aged 60 and above with comorbidities from January 10. Precaution doses of COVID-19 vaccines to all aged above 18 years were allowed at private vaccination centres from April 10.

ADVERTISEMENT

Up Next

Covid-19: Covaxin gets emergency use nod for 6-12 age group

Covid-19: Covaxin gets emergency use nod for 6-12 age group

News Wrap | Sensex & Nifty Down; SBI Tanks; Fresh Allegations Vs SEBI Chief | September 6, 2024

News Wrap | Sensex & Nifty Down; SBI Tanks; Fresh Allegations Vs SEBI Chief | September 6, 2024

Parliamentary Panel May Summon SEBI Chief Madhabi Puri Buch Amid Allegations of Corruption

Parliamentary Panel May Summon SEBI Chief Madhabi Puri Buch Amid Allegations of Corruption

Linkin Park unveil new singer, announce album 7 years after lead singer's death

Linkin Park unveil new singer, announce album 7 years after lead singer's death

India Day Parade in New York: Sonakshi Sinha-Zaheer Iqbal’s special message

India Day Parade in New York: Sonakshi Sinha-Zaheer Iqbal’s special message

Vivo T3 Ultra 5G: First Look! Flagship Killer?

Vivo T3 Ultra 5G: First Look! Flagship Killer?

ADVERTISEMENT

editorji-whatsApp

More videos

RG Kar News: স্বশরীরে আদালতে নয়, আরজি কর কাণ্ডে ধৃত সঞ্জয় রায়ের ভার্চুয়াল শুনানি হবে শুক্রবার

RG Kar News: স্বশরীরে আদালতে নয়, আরজি কর কাণ্ডে ধৃত সঞ্জয় রায়ের ভার্চুয়াল শুনানি হবে শুক্রবার

This Taiwan-Born Tech Whiz Is Helping US Counter China’s Military Advances

This Taiwan-Born Tech Whiz Is Helping US Counter China’s Military Advances

Olympian Rebecca Cheptegei Dies, Days After Being Set On Fire By Boyfriend

Olympian Rebecca Cheptegei Dies, Days After Being Set On Fire By Boyfriend

Sandip Ghosh: 'ও কিছু করেনি, কোনও কাগজপত্রও পাওয়া যায়নি', দাবি সন্দীপ ঘোষের স্ত্রীর

Sandip Ghosh: 'ও কিছু করেনি, কোনও কাগজপত্রও পাওয়া যায়নি', দাবি সন্দীপ ঘোষের স্ত্রীর

BCCI Board Secretory: আইসিসির দায়িত্বে জয় শাহ, বোর্ডের সচিব পদে কে! কবে ঠিক করবে বিসিসিআই

BCCI Board Secretory: আইসিসির দায়িত্বে জয় শাহ, বোর্ডের সচিব পদে কে! কবে ঠিক করবে বিসিসিআই

Sandeep Ghosh: RG কর মামলায় সন্দীপ ঘনিষ্ঠ প্রসূন চট্টোপাধ্যায়কে আটক করল ED

Sandeep Ghosh: RG কর মামলায় সন্দীপ ঘনিষ্ঠ প্রসূন চট্টোপাধ্যায়কে আটক করল ED

Sandip Ghosh: সন্দীপের বাড়ি থেকে শ্বশুরবাড়ি, সকাল থেকে লাগাতার ইডি হানা

Sandip Ghosh: সন্দীপের বাড়ি থেকে শ্বশুরবাড়ি, সকাল থেকে লাগাতার ইডি হানা

Aparajita Bill 2024: 'টেকনিক্যাল রিপোর্ট' না পাঠানোয় অপরাজিতা বিল আটকে, রাজ্যকে দায়ী করে জানাল রাজভবন

Aparajita Bill 2024: 'টেকনিক্যাল রিপোর্ট' না পাঠানোয় অপরাজিতা বিল আটকে, রাজ্যকে দায়ী করে জানাল রাজভবন

Goldman Sachs Recommends Selling SBI Shares, Lowers Target Price to ₹742

Goldman Sachs Recommends Selling SBI Shares, Lowers Target Price to ₹742

Cristiano Ronaldo: দু'দশকের কেরিয়ারে ৯০০ গোল, আন্তর্জাতিক ফুটবলে সর্বোচ্চ গোলদাতার রেকর্ড রোনাল্ডোর

Cristiano Ronaldo: দু'দশকের কেরিয়ারে ৯০০ গোল, আন্তর্জাতিক ফুটবলে সর্বোচ্চ গোলদাতার রেকর্ড রোনাল্ডোর

Editorji Technologies Pvt. Ltd. © 2022 All Rights Reserved.